Pulmonary hypertension associated with connective tissue diseases;Les hypertensions artérielles pulmonaires associées aux connectivites

Presse Medicale

Volumn 32, Issue 17, 2003, Pages 789-799

  Sanchez, O ^a   Sitbon, O ^a   Garcia, G ^a   Jais X ^a   Simonneau, G ^a   Humbert, Marc ^a  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTAGLANDIN; VASODILATOR AGENT;

CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HEART DISEASE; HEART MUSCLE INJURY; HUMAN; HYPOXIA; LUNG PARENCHYMA; LUNG TRANSPLANTATION; PULMONARY HYPERTENSION; REVIEW; SCLERODERMA; SHARP SYNDROME; SYNDROME; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT PLANNING; VASCULAR DISEASE; VASODILATATION;

ADULT; CALCIUM CHANNEL BLOCKERS; CAUSALITY; CONNECTIVE TISSUE DISEASES; CREST SYNDROME; ECHOCARDIOGRAPHY; EPOPROSTENOL; FEMALE; HEART CATHETERIZATION; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; IMMUNOSUPPRESSIVE AGENTS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; NITRIC OXIDE; PULMONARY CIRCULATION; RECEPTORS, ENDOTHELIN; SCLERODERMA, SYSTEMIC; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 0038353925     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Salerni R, Rodnan GP, Leon DF, Shaver JA. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977; 86:394-9.
2. Ungerer RG, Tashkin DP, Furst D et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983; 75:65-74.
3. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA, Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29:515-24.
4. Asherson RA, Higenbottam TW, Dinh Xuan AT, Khamashta MA, Hughes GR. Pulmonary hypertension in a lupus clinic: experience with twenty-four patients. J Rheumatol 1990; 17:1292-8.
5. Perez HD, Kramer N. Pulmonary hypertension in systemic lupus erythematosus: report of four cases and review of the literature. Semin Arthritis Rheum 1981; 11:177-81
6. Simonson JS, Schiller NB, Petri M, Hellmann DB. Pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1989; 16:918-25.
7. Alpert MA, Goldberg SH, Singsen BH et al. Cardiovascular manifestations of mixed connective tissue disease in adults. Circulation 1983; 68:1182-93.
8. Sullivan WD, Hurst DJ, Harmon CE et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore) 1984; 63:92-107.
9. Quismorio FP, Jr., Sharma O, Koss M et al. Immunopathologic and clinical studies in pulmonary hypertension associated with systemic lupus erythematosus. Semin Arthritis Rheum 1984; 13:349-59.
10. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 1998; 101:927-34.
11. Cool CD, Kennedy D, Voelkel NF, Tuder RM. Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection. Hum Pathol 1997; 28:434-42.
12. D'Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969; 46:428-40.
13. Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990; 21:467-74.
14. Fayemi AO. Pulmonary vascular disease in systemic lupus erythematosus. Am J Clin Pathol 1976; 65:284-90.
15. Sato M, Okazaki H, Okamoto H et al. Pulmonary hypertension in systemic lupus erythematosus: a report of an autopsied case. Intern Med 1994; 33:540-2.
16. Schwartzberg M, Lieberman DH, Getzoff B, Ehrlich GE. Systemic lupus erythematosus and pulmonary vascular hypertension. Arch Intern Med 1984; 144:605-7.
17. Hosoda Y, Suzuki Y, Takano M, Tojo T, Homma M. Mixed connective tissue disease with pulmonary hypertension: a clinical and pathological study. J Rheumatol 1987; 14:826-30.
18. Morikawa J, Kitamura K, Habuchi Y, Tsujimura Y, Minamikawa T, Takamatsu T. Pulmonary hypertension in a patient with rheumatoid arthritis. Chest 1988; 93:876-8.
19. Bunch TW, Tancredi RG, Lie JT. Pulmonary hypertension in polymyositis. Chest 1981; 79: 105-7.
20. Kishida Y, Kanai Y, Kuramochi S, Hosoda Y. Pulmonary venoocclusive disease in a patient with systemic lupus erythematosus. J Rheumatol 1993; 20:2161-2.
21. Morassut PA, Walley VM, Smith CD. Pulmonary veno-occlusive disease and the CREST variant of scleroderma. Can J Cardiol 1992; 8:1055-8.
22. Christman BW, McPherson CD, Newman JH et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992; 327:70-5.
23. Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993; 328:1732-9.
24. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995; 333:214-21.
25. Morelli S, Ferri C, Di Francesco L et al. Plasma endothelin-1 levels in patients with systemic sclerosis: influence of pulmonary or systemic arterial hypertension. Ann Rheum Dis 1995; 54:730-4.
26. Herve P, Launay JM, Scrobohaci ML et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99:249-54.
27. Klimiuk PS, Grennan A, Weinkove C, Jayson MI. Platelet serotonin in systemic sclerosis. Ann Rheum Dis 1989; 48:586-9.
28. Yuan XJ, Wang J, Juhaszova M, Gaine SP, Rubin U. Attenuated K+ channel gene transcription in primary pulmonary hypertension. Lancet 1998; 351:726-7.
29. Botney MD, Bahadori L, Gold U. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. Am J Pathol 1994; 144:286-95.
30. Humbert M, Monti G, Brenot F et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 151:1628-31.
31. Humbert M, Monti G, Fartoukh M et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998; 11:554-559.
32. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994; 144:275-85.
33. Dorfmuller P, Zarka V, Durand-Gasselin I et al. Chemokine RANTES in severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165:534-9.
34. Balabanian K, Foussat A, Doffmulfer P et al. CX(3)C Chemokine Fractalkine in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med 2002; 165:1419-25.
35. Machado RD, Pauciulo MW, Thomson JR et al. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 2001; 68:92-102.
36. Morse J, Barst R, Horn E, Cuervo N, Deng Z, Knowles J. Pulmonary hypertension in scleroderma spectrum of disease: lack of bone morphogenetic protein receptor 2 mutations. J Rheumatol 2002; 29:2379-81.
37. Williamson DJ, Hayward C, Rogers P et al. Acute hemodynamic responses to inhaled nitric oxide in patients with limited scleroderma and isolated pulmonary hypertension. Circulation 1996; 94:477-82.
38. Menon N, McAlpine L, Peacock AJ, Madhok R. The acute effects of prostacyclin on pulmonary hemodynamics in patients with pulmonary hypertension secondary to systemic sclerosis. Arthritis Rheum 1998; 41:466-9.
39. Sanchez O, Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 1999; 54:273-7.
40. Vandenbroucke JP, Rosing J, Bloemenkamp KWM et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344:1527-35.
41. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: Natural history and the importance of thrombosis. Circulation 1984; 70:580-7.
42. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76-81.
43. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993-7.
44. Sitbon O, Brenot F, Denjean A et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151:384-9.
45. Sitbon O, Humbert M, Jagot JL et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12:265-70.
46. Jolliet P, Thorens JB, Chevrolet JC. Pulmonary vascular reactivity in severe pulmonary hypertension associated with mixed connective tissue disease. Thorax 1995; 50:96-7.
47. Ocken S, Reinitz E, Strom J. Nifedipine treatment for pulmonary hypertension in a patient with systemic sclerosis. Arthritis Rheum 1983; 26:794-6.
48. Alpert MA, Pressly TA, Mukerji V et al. Acute and long-term effects of nifedipine on pulmonary and systemic hemodynamics in patients with pulmonary hypertension associated with diffuse systemic sclerosis, the CREST syndrome and mixed connective tissue disease. Am J Cardiol 1991; 68:1687-91.
49. O'Brien JT, Hill JA, Pepine CJ. Sustained benefit of verapamil in pulmonary hypertension with progressive systemic sclerosis. Am Heart J 1985; 109:380-2.
50. Niarchos AP, Whitman HH, Goldstein JE, Laragh JH. Hemodynamic effects of captopril in pulmonary hypertension of collagen vascular disease. Am Heart J 1982; 104:834-8.
51. Alpert MA, Pressly TA, Mukerji V, Lambert CR, Mukerji B. Short- and long-term hemodynamic effects of captopril in patients with pulmonary hypertension and selected connective tissue disease. Chest 1992; 102:1407-12.
52. Barst RJ, Rubin U, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334:296-302.
53. Badesch DB, Tapson VF, McGoon MD et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132:425-34.
54. Mc Laughlin VV, Genthner DE, Panella MM, Hess DM, Rich S. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130:740-3.
55. Robbins IM, Gaine SP, Schilz R, Tapson VF, Rubin U, Loyd JE. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest 2000; 117:14-18.
56. de la Mata J, Gomez-Sanchez MA, Aranzana M, Gomez-Reino JJ. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue diseases. Arthritis Rheum 1994; 37:1528-33.
57. Humbert M, Sanchez O, Fartoukh M et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999; 13:1351-6.
58. Humbert M, Maitre S, Capron F, Rain B, Musset D, Simonneau G. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998; 157:1681-5.
59. Faber CN, Yousem SA, Dauber JH, Griffith BP, Hardesty RL, Paradis IL. Pulmonary capillary hemangiomatosis: a report of three cases and a review of the litterature. Am Rev Respir Dis 1989; 140:808-13.
60. Simonneau G, Barst RJ, Galie N et al. Continuous Subcutaneous Infusion of Treprostinil, a Prostacyclin Analogue, in Patients with Pulmonary Arterial Hypertension. A double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:800-4.
61. Olschewski H, Simonneau G, Galie N et al. Inhaled Iloprost for Severe Pulmonary Hypertension. N Engl J Med 2002; 347:322-9.
62. Galie N, Humbert M, Vachiery JL et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coil Cardiol 2002; 39:1496-502.
63. Olschewski H, Walmrath D, Schermuly R, Ghofrani A, Grimminger F, Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann Intern Med 1996; 124:820-4.
64. Olschewski H, Ghofrani HA, Schmehl T et al. Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group. Ann Intern Med 2000; 132:435-43.
65. Hoeper MM, Schwarze M, Ehlerding S et al. Long-term treatment of pulmonary hypertension with aerolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342:1866-70.
66. Wilkens H, Guth A, Konig J et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104:1218-22.
67. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119-23.
68. Rubin U, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896-903.
69. Yeo PP, Sinniah R. Lupus cor pulmonale with electron microscope and immunofluroescent antibody studies. Ann Rheum Dis 1975; 34:457-60.
70. Karmochkine M, Wechsler B, Godeau P, Brenot F, Jagot JL, Simonneau G. Improvement of severe pulmonary hypertension in a patient with SLE. Ann Rheum Dis 1996; 55:561-2.
71. Dahl M, Chalmers A, Wade J, Calverley D, Munt B. Ten year survival of a patient with advanced pulmonary hypertension and mixed connective tissue disease treated with immunosuppressive therapy. J Rheumatol 1992; 19:1807-9.
72. Groen H, Bootsma H, Postma DS, Kallenberg CG. Primary pulmonary hypertension in a patient with systemic lupus erythematosus: partial improvement with cyclophosphamide. J Rheumatol 1993; 20:1055-7.
73. Goupille P, Fauchier L, Babuty D, Fauchier JP, Valat JP. Precapillary pulmonary hypertension dramatically improved with high doses of corticosteroids during systemic lupus erythematosus. J Rheumatol 1994; 21:1976-7.
74. Tanaka E, Harigai M, Tanaka M, Kawaguchi Y, Hara M, Kamatani N. Pulmonary hypertension in systemic lupus erythematosus: evaluation of clinical characteristics and response to immunosuppressive treatment. J Rheumatol 2002; 29:282-7.
75. Levine SM, Gibbons WJ, Bryan CL et al. Single lung transplantation for primary pulmonary hypertension. Chest 1990; 98:1107-1115.
76. Reitz BA, Wallwork JL, Hunt SA et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306:557-64.
77. Levy RD, Guerraty AJ, Yacoub MH, Loertscher R. Prolonged survival after heart-lung transplantation in systemic lupus erythematosus. Chest 1993; 104:1903-5.
78. Pigula FA, Griffith BP, Zenati MA, Dauber JH, Yousem SA, Keenan RJ. Lung transplantation for respiratory failure resulting from systemic disease. Ann Thorac Surg 1997; 64:1630-4.
79. Rosas V, Conte JV, Yang SC et al. Lung transplantation and systemic sclerosis. Ann Transplant 2000; 5:38-43.